Combined use of ACE-inhibitors, angiotensin II receptor antagonists or aliskiren: recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) within a European safety review
2013.06.14
Active substance: ACE-inhibitors | angiotensin II receptor antagonists or aliskiren
The BfArM issues information on the PRAC recommendation within the European safety review according to Article 31 of Directive 2001/83/EC.
To the risk assessment procedure (available in German only)
For details regarding the procedure please click on the following link to the European Medicines Agency (EMA):